Voyager Therapeutics prices $100M public offering; closes $20M Novartis private placement

Voyager Therapeutics, Inc.

Public offering of 7,777,778 shares at $9.00/share and 3,333,333 pre-funded warrants at $8.999, gross proceeds ~$100M.
Underwriters have 30-day option to purchase up to 1,666,665 additional shares at $9.00/share.
Net proceeds estimated ~$93.5M (up to ~$107.6M if option exercised) to fund AD and ALS programs and working capital.
Novartis private placement closed Jan 3, 2024: 2,145,002 shares at $9.324/share for ~$20M.
Company expects cash runway into 2027 using existing cash, collaboration reimbursements, and Novartis upfront.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Voyager Therapeutics, Inc. entered into Underwriting Agreement with Citigroup Global Markets Inc. and Guggenheim Securities, LLC valued at 7,777,778 shares of common stock at $9.00 per share; pre-funded warrants for up to 3,333,333 shares (effective 2024-01-04).

Action: entry
Agreement: underwriting
Counterparty: Citigroup Global Markets Inc. and Guggenheim Securities, LLC
Value: 7,777,778 shares of common stock at $9.00 per share; pre-funded warrants for up to 3,333,333 shares
Effective: 2024-01-04

Exact text from the filing

On January 4, 2024, Voyager Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 7,777,778 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Common Stock to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,333,333 shares of Common Stock (the “Warrant Stock”).

View on SEC.gov

Browse all material agreements →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-002271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.